How can you be sure that the clinical study won’t go terribly wrong as happened recently with the Parexel trial in London?
TGN1412 was a phase 1 clinical trial of a novel therapy never before introduced into human volunteers. By contrast Nilvadipine has been used since 1991 and millions of prescriptions have been written for this drug. Approved in Japan and countries in Europe the side effect profile is known and is generally very good. Although unexpected side effects can always occur this is mitigated by the use of drugs that have previously been widely used and studied.
Related Questions
- Is there potential overlap in what might be considered for a clinical management trial protocol and a proof of concept study?
- How can you be sure that the clinical study won’t go terribly wrong as happened recently with the Parexel trial in London?
- At what age can someone join a clinical study or trial?
